

TEAR HERE

PLEASE FILL IN BLOCK LETTERS

TEAR HERE

To,
The Board of Directors
PRAMODINI MEDICARE LIMITED

100% BOOK BUILT OFFER
ISIN: INE2JG601017

**Bid cum
Application
Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE	1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER
		Mr./Ms./M/s.
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE	Address
		Email
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.	Tel. No. (with STD code) / Mobile
		2. PAN OF SOLE / FIRST BIDDER

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL												6. INVESTOR STATUS	
												☐ Non-Resident Indian(s) (Residential basis) NRI	

For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID ☐ Registered Bilateral and Multilateral

4. BID OPTIONS (ONLY INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")													5. CATEGORY							
Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1200 Equity Shares)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1 only) (In Figures only)											
									Bid Price			Individual Discount			Net Price			"Cut-off" (Please ✓/tick)		
	8	7	6	5	4	3	2	1	3	2	1	8	2	1	3	2	1			
Option 1												Individual Bidders Non-Institutional Bidders QIB								
(OR) Option 2																				
(OR) Option 3																				

Please note that applications must be made in minimum of 2400 Equity Shares and further multiples of 1200 Equity Shares accordingly.

7. PAYMENT DETAILS [IN CAPITAL LETTERS]		PAYMENT OPTION: FULL PAYMENT ☒
---	--	--

Amount blocked (₹ in figures) **(₹ in words)** _____

ASBA

Bank A/c No.

Bank Name & Branch _____

OR

UPI ID (Maximum 45 characters)

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABBRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN IN OVERLEAF I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THIS COMMON BID CUM APPLICATION FORM GIVEN OVERLEAF

8A. SIGNATURE OF SOLE/ FIRST BIDDER		8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)		8C. MEMBERS OF THE SYNDICATE MEMBERS/ SUB-SYNDICATE MEMBER/ REGISTERED BROKER/SCSB / CDP/RTA/ AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)	
Date : _____, 2026		I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.			
		1) _____			
		2) _____			
		3) _____			

TEAR HERE

 PRAMODINI MEDICARE LIMITED An advanced way to imaging	PRAMODINI MEDICARE LIMITED	Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Members / Registered Broker / SCSB / CDP / RTA / Agent	Bid cum Application Form No.	
	INITIAL PUBLIC OFFER - NR			

[illegible]

Amount blocked (₹ in figures)		ASBA Bank A/c No./UPI ID		Stamp and Signature of SCSB Branch
Bank Name & Branch				
Received from Mr./Ms./M/s. _____				
Telephone / Mobile		Email		

TEAR HERE

PRAMODINI MEDICARE LIMITED INITIAL PUBLIC OFFER - NR		Option 1	Option 2	Option 3	Stamp & Signature of Members of the Syndicate/ Sub - Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder
	No. of Equity Shares					
	Bid Price (₹)					
	Amount Blocked (₹ in figures)					
	ASBA Bank A/c No./UPI ID _____ Bank Name & Branch _____					
					Acknowledgement Slip for Bidder	
					Bid cum Application Form No.	

Important Note: Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

PRAMODINI MEDICARE LIMITED 1

Printed by : www.mamprinttech.com

**IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS
DATED TUESDAY AUGUST 04, 2026 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.**

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL THE JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the RHP dated August 04, 2026, filed with the Registrar of Companies, Andhra Pradesh, Hyderabad (the "RoC"), I/we hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSB or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP, Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only the SCSBs (for Bids other than the Bids by Anchor Investors), and the BRLM and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP as applicable. I/we authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Offer. I/we confirm that I/we have read the RHP. My / our investment decision is solely based on the RHP as applicable and the Prospectus.

I/WE CONFIRM THAT: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity shares as nominees of any person resident outside India or foreign nationals or I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity shares on my/our own behalf through NRO account on non-repatriation basis. I/we represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) I/we have read the RHP and that my/our investment decision is based solely on the RHP; (B) I/we have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures-Disclaimer in respect of Jurisdiction" in the RHP; (C) the Equity Shares issued in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act; (D) I was/were outside of the United States at the time the Offer of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/we signed this Bid cum Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (i) if I/we are making an application to acquire any of the Equity shares for one or more managed accounts, I am/we are authorized in writing by each such managed account to subscribe to the Equity shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: (1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or the RTAs (at Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSB as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Bank, as the case may be, to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB/Registrar to the Offer shall reject the application. 3) I/we hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSBs (at Designated SCSBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide our consent to the Stock Exchanges / Sponsor Bank / NPCI / Registrar to the Offer for collecting, storing and usage validating our PAN details from the bank account where my / our amount is blocked by the relevant SCSBs.

I/we acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/We are not an OCB. For further details, see "Offer Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on pages 369 and 395, respectively of the RHP.

INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an Offer" during the Bid/ Offer period by a Bidder and not 'an Offer'.
- The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer nor RTAs/CDPs nor the SCSBs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The Price Band and the minimum Bid Lot has been decided by our Company in consultation with the Book Running Lead Manager and promoter selling shareholders. Price Band is ₹110/- to ₹118/- per Equity Share. The floor price is 11 times of the face value and the cap price is 11.80 times of the face value. Minimum Bid Lot is 2400 lots and in multiples of 1200 Equity Shares thereafter. The Bid/ Offer period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. In case of revision of the Price Band the Bid/ Offer Period will be extended for at least one additional working days subject to the total Bid/ Offer Period not exceeding 10 working days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release and also by indicating the changes on the websites of the BRLM and on the terminals of the Syndicate Members.
- Maximum and Minimum Bid Size:** In case of Individual Bidders, such number of Equity Shares such that the Bid Amount exceeds ₹ 200,000 and shall be two lots per application, subject to limits as applicable to the Bidder. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Issue Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹2,00,000 and the application is for more than two lots. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSB to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism), block their Non-Resident (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and SEBI UPI Circulars, Bidders to please ensure that SCSB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c. are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply; Bidding for an amount exceeding ₹ 5,00,000 cannot use UPI Mechanism. UPI bidders applying up to ₹ 5,00,000 can apply as per NPCI vide circular reference no. NPCI/UI/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For UPI Bidders bidding through the UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for public Officers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders with application size up to ₹ 5,00,000 bidding through the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to acquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID belonging to any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 369 of the RHP.
- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form/ Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchange do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 read with press release dated September 17, 2021 and CBDT circular no. 7 of 2022, dated March 30, 2022 and any subsequent press releases in this regard. You may be sent the RHP and the Prospectus either in physical form or electronic form or both. You shall not distribute or forward these documents and these documents are subject to the disclaimers and restrictions contained in it or accompanied in it.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act, and in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in, and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those Offer and sales occur.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in "Other Regulatory and Statutory Disclosures" and "Offer Procedure" on pages 340 and 369 of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP (if you are in India) with the terms and conditions contained therein or the Preliminary Offering Memorandum (if you are outside India) together with the terms and conditions contained therein.

Notes: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP, as applicable. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLM and the Stock Exchange.

TEAR HERE

- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer.
- In case of Bids submitted to the SCSBs, the Bidders should contact the relevant SCSB.
- In case of queries related to upload of Bids submitted to the relevant Members of the Syndicate / RTAs / Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.
- For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail ID: ipo.upi@npci.org.in and the Registrar to the Offer at Tel: 022 4961 4132; E-mail: newissue@purvashare.com
- In case of ASBA Bidders (other than 3-in-1 Bids) for a bid above ₹ 5,00,000, ensure that the bid is uploaded only by the SCSBs
- Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. on the Bid/ Offer Closing Date.

COMPANY CONTACT DETAILS	REGISTRAR TO THE OFFER
PRAMODINI MEDICARE LIMITED Registered Office: D No.- 29-4-54/K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India, 520002. Contact No.: +91 9985782727 E-mail: investors@pramodiniagnostics.com Website: www.pramodiniagnostics.com Contact person: Mr. Rushikesh Vijay Gosavi, Company Secretary & Compliance Officer	PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED Unit No. 9, Shiv Shakti Industrial Estate, J. R. Boricha Marg, Lower Parel (East), Mumbai – 400011. Tel No: 022 4961 4132 Email: newissue@purvashare.com Investor Grievance E-mail: newissue@purvashare.com Website: www.purvashare.com Contact Person: Ms. Deepali Gaonkar SEBI Registration Number: INR000001112



PRAMODINI MEDICARE LIMITED
CIN: U85110AP2000PLC035231

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
D. No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India – 520002	N.A.	Mr. Rushikesh Vijay Gosavi, Company Secretary & Compliance Officer	Email: investor@pramodinidiagnostics.com Telephone: +91 99857 82727	www.pramodinidiagnostics.com

THE PROMOTERS OF OUR COMPANY ARE THE PROMOTERS OF OUR COMPANY DR. CHALASANI KULDEEP KUMAR, DR. CHALASANI KAVITHA, MS. CHALASANI DURGA AASHRITHA, MS. CHALASANI LALITHAKUMARI AND M/S. SRI RAM MEDICARE PRIVATE LIMITED

DETAILS OF OFFER TO PUBLIC, PROMOTERS SELLING SHAREHOLDERS

TYPE	FRESH OFFER	SIZE OF OFFER FOR SALE	TOTAL OFFER SIZE	ELIGIBILITY AND SHARE RESERVATION AMONG QIBs, NIIs AND IIs
Fresh Issue & Offer for Sale	Up to 53,50,800 Equity Shares aggregating up to [●] Lakhs.	Up to 5,00,400 Equity Shares aggregating up to ₹ [●] Lakhs	Up to 58,51,200 Equity Shares aggregating up to ₹ [●] Lakhs	The Offer is being made in Terms of Regulation 229 (2) and 253 (1) and 253(2) of the SEBI ICDR Regulations 2018 and as amended. For details in relation to share reservation among QIBs, Non-Institutional Bidders and Individual Bidder, see “Offer Structure” beginning on page 364 of the Red Herring Prospectus.

OFS: Offer for Sale

DETAILS OF OFFER FOR SALE, PROMOTER SELLING SHAREHOLDERS AND THEIR WEIGHTED AVERAGE COST OF ACQUISITION

NAME	CATEGORY OF SHAREHOLDER	NO. OF SHARES OFFERED	WACA PER EQUITY SHARE (IN ₹)*
Dr. Chalasani Kuldeep Kumar	Promoter Selling Shareholder	Up to 2,14,400 Equity Shares aggregating up to ₹ [●] Lakhs.	6.99
Dr. Chalasani Kavitha	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares aggregating up to ₹ [●] Lakhs.	6.23
M/S. Sri Ram Medicare Private Limited	Promoter Selling Shareholder	Up to 1,43,000 Equity Shares aggregating up to ₹ [●] Lakhs.	4.25

* As certified by Statutory Auditor of our Company, by way of their certificate dated August 03, 2026.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public offer of our Company, there has been no formal market for the Equity Shares. The face value of Equity Shares is ₹10/- each. The Floor Price, Cap Price and Offer Price (determined by our Company and the promoter selling shareholders in consultation with the Book Running Lead Manager, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment of market demand for the Equity Shares by way of Book Building Process as stated in “Basis for Offer Price” beginning on page 106 should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and bidders should not invest any funds in the offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the offer. For taking an investment decision, Bidders must rely on their own examination of our company and the offer, including the risks involved. The equity shares in the offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” on page 24 of this Red Herring Prospectus

COMPANY’S, PROMOTER’S AND PROMOTER SELLING SHAREHOLDER’S ABSOLUTE RESPONSIBILITY

Our company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our company and the offer, which is material in the context of the offer, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. The promoter selling shareholders, accepts responsibility for and confirms only the statements expressly and specifically made by him in this Red Herring Prospectus to the extent of information specifically pertaining to them and their respective portion of the offered Shares and assumes responsibility that such statements are true and correct in all material respects and not misleading in any material respect. The promoter selling Shareholders assume no responsibility, as a promoter selling Shareholders, for any other statement in this Red Herring Prospectus, including, inter alia, any of the statements made by or relating to our company or our company’s business or any other person(s).

LISTING

The equity shares offered through the Red Herring Prospectus are proposed to be listed on Emerge Platform of NSE (“NSE EMERGE”). Our company has received “In-Principle” approval from the NSE Emerge for using its name in the offer document for the listing of the Equity Shares, pursuant to letter dated July 10, 2026. For the purpose of the offer, the designated stock exchange shall be NSE.

BOOK RUNNING LEAD MANAGER TO THE OFFER

Name and Logo	Contact Person	Email & Telephone
---------------	----------------	-------------------

 Smart Horizon Capital Advisors Private Limited	Mr. Parth Shah	E-mail: director@shcapl.com Telephone: 022 - 28706822
REGISTRAR TO THE OFFER		
Name and Logo	Contact Person	Email & Telephone
 Purva Shareregistry (India) Private Limited	Ms. Deepali Gaonkar	E-mail: newissue@purvashare.com Telephone: 022 - 49614132
BID/OFFER PROGRAMME		
ANCHOR INVESTOR BID/ OFFER PERIOD: TUESDAY, AUGUST 11, 2026*	BID/OFFER OPENS ON: WEDNESDAY, AUGUST 12, 2026 *	BID/OFFER CLOSES ON: FRIDAY, AUGUST 14, 2026 **

*Our Company and the Promoter Selling Shareholders in consultation with the BRLM may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Offer Period shall be one Working Day prior to the Bid/Offer Opening Date. **Our Company and the Promoter Selling Shareholders may, in consultation with the BRLM, consider closing the Bid/Offer Period for QIBS one Working Day prior to the Bid/ Offer Closing Date in accordance with the SEBI ICDR Regulations.

The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Offer Closing Day.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

 (Please scan this QR code to Red Herring Prospectus and Abridged Prospectus)	The following is a general summary of certain disclosures in the Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Red Herring Prospectus, which is available at the website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in, at the websites of the Emerge Platform of NSE at www.nseindia.com, at the website of the Company at www.pramodiniagnostics.com and the website of the Book Running Lead Managers at www.shcapl.com. References below are to the page numbers of the Red Herring Prospectus dated August 04, 2026. Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the Red Herring Prospectus.
---	---

1. Summary of the Primary Business

Our Company is a diagnostic service provider in India. We provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The services offered at each location vary based on the scope agreed under the respective MOUs. We provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions.

a) The business overview including products/services offered by the Company: Our diagnostic services include a comprehensive range of offerings: (i) "Radiology" which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) "Clinical Laboratory" which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) "Nuclear Medicine" which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy. We also provide teleradiology services through our registered office situated at Vijayawada which functions on a 24x7 basis throughout the year.

b) Description of industries served and typical customer/clients of the Company: Our business operates across four key models namely 1. Public Private Partnership (with government hospitals and government teaching hospitals) 2. Private Private Partnership (with private sector hospitals) 3. Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and 4. Private Centres (standalone centre).

c) Segment reporting details and their revenue contribution for the reporting periods: Our Company is engaged in the business of providing diagnostic service and providing a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges. For further details, please see chapter titled "Our Business-Revenue Break-Up" on page 139.

d) Key Geographies Served: For FY 2025-26, our Company generated total revenue from operations of ₹6228.75 lakhs. The majority of the revenue was contributed by Andhra Pradesh (61.90%) and Karnataka (20.82%), followed by Uttar Pradesh (10.01%) and West Bengal (7.27%). The remaining revenue was generated from several other states across India, each contributing a relatively smaller share, reflecting the Company's geographically diversified customer base. For further details, please see chapter titled "Our Business-Revenue Break-Up" on page 139.

e) Revenue concentration among top 5 customers: The contribution of the top five customers in Revenue is Rs 4,006.31 lakhs (64.32%) for FY 2025-26, Rs. 2,878.02 lakhs (75.27 %) for FY 2024-25 and Rs. 2,849.16 lakhs (80.87%) for FY 2023-24.

f) Key manufacturing or other facilities: We have 3 (three) establishments comprising our Registered office cum diagnostic and Imaging Centre, Branch office cum Diagnostic and Imaging Centre and Lab Processing Unit in Vijayawada to support business operations and patient servicing.

g) Business strengths and strategies:

Our business strengths are:

- Establishing a Strategic presence across various states of India
- Strengthening Our Network with Diversified Models
- Technical Capability with robust IT Infrastructure
- Dedicated Management Team with Significant Industry Experience
- Track record of revenue and financial performance
- Diverse Customer cum Patient Base

Our business strategies are:

- Expanding geographic footprint across the India
- Increase in capacities at our existing diagnostic facilities
- Expand our business and geographical footprint through opportunistic acquisitions
- Continue to improve profitability and efficiency
- Enhancing our brand image

For further details, please refer to the chapter titled “Our Business” beginning on page 135 of the Red Herring Prospectus.

2. Summary of the Industry

- The Indian healthcare sector, valued at Rs. 9,42,590 crore (US\$ 110 billion) in 2016 and Rs. 31,87,668 crore (US\$ 372 billion) in 2023, is projected to reach Rs. 54,67,022 crore (US\$ 638 billion) by 2025, growing at a robust 17.5-22.5% CAGR, driven by innovation across hospitals, pharmaceuticals, and diagnostics.
- The global remote patient monitoring market is projected to expand at a CAGR of 12.7% to reach US\$ 56.94 billion by 2030.
- India’s hospital market is expected to be valued at US\$ 135.3 billion in FY2026 and is projected to reach US\$ 202.5 billion by 2030, growing at a CAGR of ~10.6%.

For further details, please refer to the chapter titled “Industry Overview” beginning on page 118 of the Red Herring Prospectus.

3. Promoters of our Company

Sr. No.	Name of the Promoter	Individual/Corporate	Experience & Educational Qualification
1.	Dr. Chalasani Kuldeep Kumar	Individual	He is the Promoter, Chairman and Managing Director of our Company. He completed his degree of Bachelor of Medicine & Bachelor of Surgery (Faculty of Medicine) from Nagpur University in April 2002. Thereafter, he completed his degree of Doctor of Medicine (Radio-Diagnosis) from Rajiv Gandhi University of Health Sciences, Karnataka in March 2006. In his previous stint, he served as Chief Resident at Grant Medical College & Sir J.J. Group of Hospitals Mumbai. He has also worked as an Associate Professor at Dr Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation in April 2015. He holds life membership of Indian Radiological & Imaging Association through the Andhra Pradesh state chapter and is also a life member of the Indian Medical Association. He is having overall work experience of more than 20 years in the field of Medicine, Surgery and Radio-Diagnosis. He has been associated with our Company since 2015 and has experience of more than 10 years in our Company.
2.	Dr. Chalasani Kavitha	Individual	She is the Promoter and Non-Executive Director of our Company. She completed her Bachelor of Medicine and Bachelor of Surgery (MBBS) from Kasturba Medical College, Manipal, under Manipal Academy of Higher Education in August 1999. She also completed her Master of Surgery (MS) in Obstetrics and Gynecology from Kasturba Medical College, Manipal, under Manipal Academy of Higher Education in September 2003. She has also obtained the Diplomate of the National Board (DNB) in Obstetrics and Gynaecology from the National Board of Examinations, New Delhi in 2005. Further, she obtained a fellowship in Gynecology Endoscopy from Rajiv Gandhi University of Health Science, Karnataka in March 2008. Further, she was awarded Dr. P. Amini Memorial Award for being the best outgoing student in M.D. (Obstetrics & Gynecology) in the examination held in 2003. She has been associated with our Company since the year 2015 and has experience of more than 20 years in the field of Obstetrics and Gynecology.
3.	Ms. Chalasani Durga Aashritha	Individual	She is the Promoter and Non-Executive Director of our Company. She is currently pursuing her Third Professional MBBS (Part II) course at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation. She has been associated with our Company since September 2025.
4.	Ms. Chalasani	Individual	Ms. Chalasani Lalithakumari is the Promoter of our Company. She completed her bachelor of

	Lalithakumari		Medicine and Surgery from Andhra University in the year 1974. Further, she completed diploma in Gynecology and obstetrics from Nagarjuna University in the year 1978. She associated with Sri Ram Medicare Private Limited since 2012.
5.	M/s. Sri Ram Medicare Private Limited	Corporate	M/s. Sri Ram Medicare Private Limited was incorporated on March 15, 2012 as a private limited company registered under the Companies Act, 1956 via certificate of incorporation dated March 15, 2012 issued by the Registrar of Companies, Andhra Pradesh vide CIN U85100AP2012PTC079774 and is not listed on any stock exchange.

For further details, please refer to the chapter titled “Our Promoters and Promoter Group” beginning on page 193 of the Red Herring Prospectus.

4. Objects of the Offer

The Offer comprises a Fresh Issue of up to 53,50,800 equity shares of face value ₹ 10, aggregating up to ₹ [●] lakhs by our Company and an Offer for Sale of up to 5,00,400 equity shares of face value ₹ 10, aggregating to ₹ [●] lakhs by the Promoter Selling Shareholders.

Our Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

Sr. No.	Particulars of Object	Description
1.	Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres (₹4,514.85 lakhs)	Our Company intends to purchase and install medical equipments across three of our existing diagnostic centres. At Hubli (Karnataka), we propose to expand our capacity by installing additional equipments. At Manjeri (Kerala), where operations are yet to commence, we intend to install the required medical equipments. Further, at Vijayawada (Andhra Pradesh), out of three proposed equipments only one equipment will be replaced with existing equipment. Also, we intend to leverage our operational experience and further expand our operations in proposed centre in Bangalore in the state of Karnataka.
3.	General corporate purposes and unidentified inorganic acquisition;	We will evaluate inorganic growth opportunities, keeping in line with our strategy to grow and develop our market share or to add service offerings.

For further details, please refer to the chapter titled “Objects of the Offer” beginning on page 97 of the Red Herring Prospectus.

5. Pre and post offer shareholding of Promoter(s), members of the Promoter Group and top 10 shareholders.

Sr. No.	Particulars	Pre-Offer as at the date of the Red Herring Prospectus		Post-Offer shareholding as at Allotment*			
		Number of Equity Shares of face value ₹10 each	Percentage of total pre-Offer paid up Equity Share capital	At the lower end of the Price Band (₹[●])		At the upper end of the Price Band (₹[●])	
				Number of Equity Shares of face value ₹10 each	Percentage of total post -Offer paid up Equity Share capital	Number of Equity Shares of face value ₹10 each	Percentage of total post -Offer paid up Equity Share capital
Promoters							
1	Dr. Chalasani Kuldeep Kumar	80,87,586	48.44%	[●]	[●]	[●]	[●]
2	Dr. Chalasani Kavitha	16,34,737	9.79%	[●]	[●]	[●]	[●]
3	M/s Sri Ram Medicare Private Limited	45,87,154	27.48%	[●]	[●]	[●]	[●]
	Total (A)	1,43,09,477	85.71%	[●]	[●]	[●]	[●]
Promoter Group							
	NA	NA	NA	NA	NA	NA	NA
	Total (B)	-	-	-	-	-	-
Additional top 10 shareholders							
1.	Mr. Yash Hitesh Patel	8,34,756	5.00%	[●]	[●]	[●]	[●]
2.	Ms. Yashvi Hitesh Patel	7,92,831	4.75%	[●]	[●]	[●]	[●]
3.	Ms. Sumita Mishra	3,33,892	2.00%	[●]	[●]	[●]	[●]
4.	Mr. Sadineni Raghu Teja	2,14,214	1.28%	[●]	[●]	[●]	[●]
5.	Mr. Siva Rama Krishna Prasad	83,863	0.50%	[●]	[●]	[●]	[●]

	Attluri						
6.	Ms. Karri Mani Kumari	41,925	0.25%	[●]	[●]	[●]	[●]
7.	Mr. Swapnil Sudhakar Rao Topale	41,925	0.25%	[●]	[●]	[●]	[●]
8.	Mr. Jay Ashok Shah	20,956	0.13%	[●]	[●]	[●]	[●]
9.	Ms. Priti Surya Prakash Mishra	20,956	0.13%	[●]	[●]	[●]	[●]
10.	NA	NA	NA	NA	NA	NA	NA
	Total (C)⁽²⁾	23,85,318	14.29%	[●]	[●]	[●]	[●]
	Total (A+B+C)	1,66,94,795	100.00%	[●]	[●]	[●]	[●]

Notes:

- 1) Based on the Offer Price of ₹ [●] and subject to finalization of the basis of allotment.
2) As on the date of the Red Herring Prospectus, we have total 12 (Shareholders), out of which 9 are Public Shareholders.

For detailed information on the “Capital Structure”, please refer on page 82 of the Red Herring Prospectus.

6. Summary of Restated Financial Information

The following details are derived from the Restated Consolidated Financial Information for the Financial Years ended March 31, 2026, March 31, 2025 and March 31, 2024:

(₹ in Lakhs)

Particulars	As At 31st March, 2026	As At 31st March, 2025	As At 31st March, 2024
Share Capital	1,669.48	128.42	128.42
Net Worth#	5,315.17	3,577.45	2,474.69
Revenue from operations\$	6,337.85	3,854.63	3,579.40
EBITDA	3,090.26	2,096.61	1,539.07
Profit after Tax	1,737.73	1,102.76	693.01
Basic Earnings Per Share@	10.41	6.67	4.30
Diluted Earnings Per Share@	10.41	6.67	4.30
Return on Equity / Net Worth	39.08%	36.44%	32.76%
*Net Asset Value per Equity Shares (Post Bonus)	31.84	21.43	14.82
^Total Borrowings (as per Restated)	1,784.81	1,081.42	1,196.23
Cash flow from operating activities	2,539.05	2,218.29	1,000.04
Cash flow from investing activities	(3,062.67)	(1,471.73)	(152.81)
Cash flow from financing activities	573.17	(239.10)	(1,081.01)

Notes:

Net Worth = Restated Equity Share Capital plus Restated Reserves & Surplus

\$ Revenue = Restated Revenue from operations

@ Earnings per share (Basic & diluted) = Restated profit after tax for the period divided by Restated weighted average number of Equity Shares outstanding during the period

*Net Asset Value per Equity Share = Restated Net worth divided by Restated weighted average number of Equity Shares outstanding during the period

^Total Borrowings = Restated Long-Term Borrowings Plus Restated Short-Term Borrowings

For details, see “Restated Consolidated Financial Information”, “Other Financial Information” and “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” on pages 203, 302 and 309, respectively.

7. Summary of Key Performance Indicators

Details of our KPIs for the Fiscal 2026, Fiscal 2025 and Fiscal 2024:

(₹ in Lakhs, otherwise mentioned)

Key Financial Performance*	March 31, 2026	March 31, 2025	March 31, 2024
Revenue from Operations ⁽¹⁾	6,228.75	3,823.77	3,522.95
EBITDA ⁽²⁾	3,090.35	2,096.61	1,553.47
EBITDA Margin (%) ⁽³⁾	49.61%	54.83%	44.10%
Profit/(loss) after tax for the year ⁽⁴⁾	1,737.73	1,102.76	693.01
PAT Margin (%) ⁽⁵⁾	27.90%	28.84%	19.67%
Return on Equity (RoE) (%) ⁽⁶⁾	39.08%	36.44%	32.76%
Return on Capital Employed (%) ⁽⁷⁾	34.66%	36.48%	31.90%
Net Capital Turnover Ratio (in Times) ⁽⁸⁾	9.00	6.38	8.73
Debt to Equity Ratio (in Times) ⁽⁹⁾	0.34	0.30	0.48

Key Financial Performance*	March 31, 2026	March 31, 2025	March 31, 2024
Current Ratio (in times) ⁽¹⁰⁾	1.26	1.58	1.28

As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated July 28, 2026.

Notes:

- (1) Revenue from operations means revenue from sales and other operating revenues
(2) EBITDA is calculated as Profit before tax + Depreciation + Finance Cost - Other Income
(3) 'EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations
(4) PAT is calculated as Profit before tax – Tax Expenses
(5) 'PAT Margin' is calculated as PAT for the year divided by revenue from operations
(6) Return on Equity is the ratio of Profit after Tax and Average Shareholder Equity
(7) Return on Capital Employed is calculated as follows: Profit before tax + Finance Costs (EBIT) divided by (Tangible Net Worth + Total Debt + Deferred Tax Liabilities)
(8) Net Capital Turnover Ratio is calculated as revenue from operations divided by average working capital.
(9) Debt to Equity ratio is calculated as Long Term Debt + Short Term Debt divided by equity
(10) Current Ratio is calculated by dividing Current Assets by Current Liabilities

For further details, please refer to the chapter titled "Basis for Offer Price" beginning on page 106 of the Red Herring Prospectus.

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the Red Herring Prospectus:

- 1) A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations.
- 2) Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
- 3) We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition.
- 4) We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations.
- 5) We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations.
- 6) Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
- 7) We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance.
- 8) Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition.
- 9) Our Company is not having any exact comparable Indian peer which have similar business to our Company.
- 10) We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.

For further details, please refer to the chapter titled "Risk Factor" beginning on page 24 of the Red Herring Prospectus. Investors are advised to read the risk factors carefully before making an investment decision in the Offer.

9. The details of weighted average cost of acquisition of shares for Promoters (including our Promoter Selling Shareholders)

The weighted average cost of acquisition of Equity Shares of our Promoters (including our Promoter Selling Shareholders), are as follows:

Types of transactions	Weighted average cost of acquisition per Equity Share (in ₹)	Cap Price is 'X' times the weighted average cost of acquisition *	Range of acquisition price: per Equity Share: lowest price – highest price (in ₹) *
Weighted average cost of acquisition of primary issuances as per paragraph (a) above	NA	NA	NA

Weighted average cost of acquisition for secondary transactions as per paragraph (b) above	34.95	[●]	[●]
Weighted average cost of acquisition for past 5 primary issuances / secondary transactions, as per paragraph (c) above	NA	NA	NA

* To be included upon finalization of the Price Band.

* As certified by Statutory Auditor, Chartered Accountants, by way of their certificate dated August 03, 2026.

For further details, please refer to the chapter titled “Basis for Offer Price” beginning on page 106 of the Red Herring Prospectus.

10. Board of Directors and Key Managerial Personnel

S. No.	Name	Designation
Board of Directors		
1.	Dr. Chalasani Kuldeep Kumar	Chairman and Managing Director
2.	Dr. Chalasani Kavitha	Non-Executive Director
3.	Ms. Chalasani Durga Aashritha	Non-Executive Director
4.	Mr. A Ajay Kumar	Non-Executive Independent Director
5.	Dr. Eshwar Chandra Nandury	Non-Executive Independent Director
6.	Mr. Manas Dash	Non-Executive Independent Director
Key Managerial Personnel		
7.	Mr. Rushikesh Vijay Gosavi	Company Secretary and Compliance Officer
8.	Mr. Rajkamal Kona	Chief Financial Officer (CFO)

For further details, please refer to the chapter titled “Our Management” beginning on page 177 of the Red Herring Prospectus.

11. Auditor Qualifications

The Statutory Auditors of our Company have not expressed any qualification, reservation, adverse remark, matter of emphasis, or other observation on our financial statements for the periods covered in the Red Herring Prospectus.

12. Summary table of Outstanding Litigations

A. Total number of outstanding litigations against our Company and amount involved:

Name of Entity	Criminal Proceedings	Tax Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs. In Lakhs)
By the Company	Nil	Nil	Nil	Nil	Nil
Against the Company	Nil	7	Nil	1	0.39
By our Directors	Nil	Nil	Nil	Nil	Nil
Against the Directors	Nil	Nil	Nil	Nil	Nil
By Promoters	Nil	Nil	Nil	1	Nil
Against Promoters	Nil	12	Nil	1	1.51
By our KMPs & SMPs	Nil	Nil	Nil	Nil	Nil
Against the KMPs & SMPs	Nil	Nil	Nil	Nil	Nil
By the Group Companies / Entities	Nil	Nil	Nil	Nil	Nil
Against the Group Companies / Entities	Nil	10	Nil	1	10.08

*Our Promoters are also the director of the Company. Hence litigations against them have not been included under the heading of director to avoid repetition.

For further details, please refer to the chapter titled “Outstanding Litigation and Material Developments” beginning on page 327 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the “Securities Act”) or any state securities

laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold outside the United States in offshore transactions in reliance on Regulations under the Securities Act and in compliance with the applicable laws of the jurisdiction where such offers and sales occur. There will be no public offering of the Equity Shares in the United States.

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in this Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of Sole Bidder / First Bidder should be exactly the same as it appears in the depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an "indication to make an Offer" and not "an Offer".
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCBS Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band :** In case of an upward revision in the Price Band, Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment exceed ₹200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCBSs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, UPI Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the Sole Bidder / First Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of Sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c. are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Bidding for an amount exceeding ₹ 5,00,000 cannot use UPI Mechanism. UPI bidders applying up to ₹ 5,00,000 can apply as per NPCI vide circular reference no. NPCI/UI/OC No. 127/2021-22 dated December 9, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - For UPI Bidders bidding through the UPI Mechanism.**
 - Please ensure that your Bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) UPI Bidders with application size up to ₹ 5,00,000 bidding through the UPI Mechanism may apply through the SCBSs and mobile applications whose names appear on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID belonging to any third party.
 - UPI Bidders bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 369 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCBSs/Registered Brokers/ RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgement Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to Issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with the CBDT notification dated February 13, 2020 and press release dated June 25, 2021, read with press release dated September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022, read with press release dated March 28, 2023.

OFFER STRUCTURE

This Offer is being made by way of Book Building Process.

Particulars of the Offer	Market Maker Reservation Portion	QIBs ⁽⁴⁾	Non-Institutional Bidders	Individual Investors/Bidders (who applies for minimum application size)
Number of Equity Shares available for allocation or allotment ⁽²⁾	Up to 3,36,000 Equity Shares	Not more than 25,32,000 Equity Shares of face value of ₹10/- each.	Not less than 9,60,000 Equity Shares of face value of ₹10/- each available for allocation or Offer less allocation to QIB Bidders and Individual Investors.	Not less than 20,23,200 Equity Shares of face value of ₹10/- each available for allocation or Offer less allocation to QIB Bidders and Non - Institutional Investors
Percentage of offer size available for allocation or allotment	5.74 % of the offer size	Not more than 50% of the Net Offer being available for allocation to QIB Bidders. However, up to 5% of the Net QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion (excluding the Anchor investor portion). The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion	Not less than 15% of the Net Offer. Further, one third of the portion available to non-institutional investors shall be reserved for Bidders with application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs. Two third of the portion available to non-institutional investors shall be reserved for Bidders with application size of more than ₹10 lakhs. Provided that the unsubscribed portion in either the subcategories as mentioned above could be allocated to Bidders in the other sub-category of Non-Institutional Bidders.	Not less than 35% of the Net Offer.
Basis of Allotment ⁽³⁾	Firm Allotment.	Proportionate as follows (excluding the Anchor investor portion): Up to 60,000 Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and Up to 11,71,200 Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of QIB Portion (of up to 13,60,800 Equity Shares) may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price. 40% of the Anchor Investor Portion shall be reserved for (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for life insurance companies and pension funds subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price.	Proportionate basis subject to the availability of shares in non-institutional investors' category, the allotment of equity shares to each non-institutional category shall not be less than the minimum application size in non-institutional investor category, and the remaining shares, if any, shall be allotted on a proportionate basis, the 1,200 Equity Shares shall be allotted in multiples of 1,200 Equity Shares. For details, please refer to section titled "Offer Procedure" beginning on page 369 of the RHP.	Proportionate basis subject to minimum allotment of 2,400 Equity Shares. For details, please refer to section titled "Offer Procedure" beginning on page 369 of the RHP.
Mode of Bid	Only through ASBA Process.	ASBA only except for Anchor Investors ⁽⁴⁾	Only through ASBA Process.	Through ASBA Process, through Banks or by using UPI ID for payment.
Mode of Allotment ⁽⁴⁾	Compulsorily in dematerialized form			
Minimum Bid Size	1,200 Equity Shares in multiple of 1,200 Equity shares.	Such number of Equity Shares and in multiples of 1,200 Equity Shares that the Bid Amount exceeds ₹ 200,000 for more than two lots.	Such number of Equity shares in multiple of 1,200 Equity shares such that the application is for more than two lots.	2,400 Equity Shares in multiple of 1,200 Equity shares such that Bid Amount exceeds ₹ 200,000 and shall be two lots per application.
Maximum Bid Size	1,200 Equity Shares	Such number of Equity Shares in multiples of 1,200 Equity Shares not exceeding the size of the Net Offer (excluding the Anchor portion), subject to applicable limits.	Such number of Equity Shares in multiples of 1,200 Equity Shares not exceeding the size of the Net Offer (excluding the QIB portion), subject to limits as applicable to the Bidder	Such number of Equity Shares in multiples of 1,200 Equity Shares such that the application size doesn't exceed 2 lots per application. subject to limits as applicable to the Bidder.
Bid Lot	1,200 Equity Shares and in multiples of 1,200 Equity Shares thereafter			
Trading Lot	1,200 Equity Shares, however, the Market Makers may accept odd lots if any in the market as required under the SEBI ICDR Regulations	1,200 Equity Shares and in multiples thereof	1,200 Equity Shares and in multiples thereof.	1,200 Equity Shares and in multiples thereof
Who can apply? ⁽⁵⁾	Market Maker.	Public financial institutions as specified in Section 2(72) of the Companies Act 2013, scheduled commercial banks, multilateral and bilateral development financial institutions, mutual funds registered with SEBI, FPIs other than individuals, corporate bodies and family offices, VCFs, AIFs, FVCIs, registered with SEBI, state industrial development corporation, insurance company registered with IRDAI, provident fund with minimum corpus of ₹2500 lakhs, pension fund with minimum corpus of ₹2500 lakhs, National Investment Fund set up by the Government of India, insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important NBFCs, in accordance with applicable laws including FEMA Rules.	Resident Indian individuals, Eligible NRIs, HUFs (in the name of Karta) companies, corporate bodies, scientific institutions, societies, family offices, trusts, FPIs who are individuals, corporate bodies and family offices which are recategorized as Category II FPIs and registered with SEBI.	Resident Indian individuals, HUFs (in the name of Karta) and Eligible NRIs.
Terms of Payment	In case of all other Bidders: Full Bid Amount shall be blocked by the SCBSs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form. In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids ⁽⁴⁾ .			

⁽⁴⁾ Assuming full subscription in the Offer.

⁽⁵⁾ SEBI through its circular (SEBI/HO/CFD/DIL2/CIR/P/2022/45) dated April 5, 2022, has prescribed that all individual investors applying in initial public offerings opening on or after May 1, 2022, where the application amount is up to ₹500,000, shall use UPI. Individual investors Bidding under the Non-Institutional Portion Bidding for more than ₹200,000 and up to ₹500,000, using the UPI Mechanism, shall provide their UPI ID in the Bid-cum-Application Form for Bidding through syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers. Further SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/2022/75 dated May 30, 2022, has mandated that ASBA applications in public issues shall be processed only after the application monies are blocked in the bank accounts of the investors. Accordingly, Stock Exchanges shall, for all categories of investors viz. QIBs, NRIs and IIs and also for all modes through which the applications are processed, accept the ASBA applications in their electronic book building platform only with a mandatory confirmation on the application monies blocked.

- Our Company and Promoter Selling Shareholders in consultation with the Book Running Lead Manager may allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Offer Price, on a discretionary basis, subject to there being (i) a maximum of two Anchor Investors, where allocation in the Anchor Investor Portion is up to ₹200 Lakhs, (ii) a minimum of two and maximum of fifteen Anchor Investors, where the allocation under the Anchor Investor Portion is more than ₹200 Lakhs but up to ₹2,500 Lakhs under the Anchor Investor Portion, subject to a minimum Allotment of ₹100 Lakhs per Anchor Investor, and (iii) in case of allocation above ₹2,500 Lakhs under the Anchor Investor Portion, a minimum of five such investors and a maximum of fifteen Anchor Investors for allocation up to ₹2,500 Lakhs, and an additional ₹2,500 Lakhs or part thereof will be permitted, subject to minimum allotment of ₹100 Lakhs per Anchor Investor. An Anchor Investor will make a minimum Bid of such number of Equity Shares, that the Bid Amount is at least ₹200 Lakhs. One-third of the Anchor Investor Portion shall be reserved for allocation to domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. However, with effect from December 1, 2025, pursuant to the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Third Amendment) Regulations, 2025, 40% of the Anchor Investor Portion shall be reserved for, (i) 33.33% shall be available for allocation to domestic Mutual Funds and (ii) 6.67% shall be available for allocation to life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies, and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription under (ii) above, the allocation may be made to domestic Mutual Funds.
- The SEBI ICDR Regulation, 2018, permits the offer of securities to the public through the Book Building Process, which states that not less than 35% of the Net Offer shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Offer shall be available for allocation to Non Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of Equity Shares in the Non - Institutional investors category, the allotment to each Non-Institutional Investors shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) Regulations, 2018. Not more than 50% of the Net Offer shall be allocated to QIBs, subject to valid Bids being received at or above the Offer Price.
- In the event that a Bid is submitted in joint names, the relevant Bidders should ensure that the depository account is also held in the same joint names and the names are in the same sequence in which they appear in the Bid cum Application Form. The Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such First Bidder would be required in the Bid cum Application Form and such First Bidder would be deemed to have signed on behalf of the joint holders. Our Company reserves the right to reject, in its absolute discretion, all or any multiple Bids in any or all categories.
- Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Offer Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.
- The Bids by FPIs with certain structures as described under "Offer Procedure" on page 369 and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares Allocated and Allotted to such successful Bidders (with same PAN) may be proportionately distributed.
- Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Offer Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.

**COMMON BID
REVISION FORM**

PRAMODINI MEDICARE LIMITED - INITIAL PUBLIC OFFER - NR

Registered Office: Address: D. No. 29-4-54K, CSI Complex, Prakasam Road, Suryanopet, Vijayawada, Andhra Pradesh, India, 520002.

Contact No.: +91 9985782727; E-mail: investors@pramodiniagnostics.com; Website: www.pramodiniagnostics.com;

Contact person: Mr. Rushikesh Vijay Gosavi, Company Secretary and Compliance Officer, Corporate Identity Number: U85110AP2000PLC035231

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIS, FPIs, FVCIS AND REGISTERED MULTI LATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS ETC. APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors
PRAMODINI MEDICARE LIMITED

100% BOOK BUILT OFFER
ISIN: INE2JG601017

**Bid cum
Application
Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER	
Mr./Ms./M/s. _____	
Address _____	
Email _____	
Tel. No. (with STD code) / Mobile _____	
2. PAN OF SOLE / FIRST BIDDER	

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL	
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID	

PLEASE CHANGE MY BID

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1200 Equity Shares)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures Only)					"Cut-off" (Please ✓ tick)	
	(In Figures)								(In Figures Only)						
	8	7	6	5	4	3	2	1	Bid Price	Individual Discount	Net Price				
Option 1									3	2	1	3	2	1	
(OR) Option 2															
(OR) Option 3															

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1200 Equity Shares)								Price per Equity Share (₹) (Price in multiples of ₹ 1/- only) (In Figures Only)					"Cut-off" (Please ✓ tick)	
	(In Figures)								(In Figures Only)						
	8	7	6	5	4	3	2	1	Bid Price	Individual Discount	Net Price				
Option 1									3	2	1	3	2	1	
(OR) Option 2															
(OR) Option 3															

Please note that applications must be made in minimum of 2400 lots and further multiples of 1200 Equity Shares accordingly.

6. PAYMENT DETAILS [IN CAPITAL LETTERS]		PAYMENT OPTION : FULL PAYMENT ☒
Additional Amount Blocked (₹ in figures) _____ (₹ in words) _____		
ASBA Bank A/c No. _____		
Bank Name & Branch _____		
UPI ID (Maximum 45 characters) _____		
I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDERTAKING" AS GIVEN ALONG WITH THE COMMON BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THIS BID REVISION FORM GIVEN OVERLEAF.		

7A. SIGNATURE OF SOLE/ FIRST BIDDER	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)		7C. MEMBERS OF THE SYNDICATE MEMBERS/ SUB - SYNDICATE MEMBER/ REGISTERED BROKER/ SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)
	I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.		
	1) _____		
	2) _____		
Date : _____, 2026			

TEAR HERE

	PRAMODINI MEDICARE LIMITED	Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Members / Registered Broker / SCSB / CDP / RTA / AGENTS	Bid cum Application Form No.
BID REVISION FORM - INITIAL PUBLIC OFFER - NR			

DPID / CLID	_____	PAN of Sole / First Bidder	_____
Additional Amount Blocked (₹ in figures)	_____	ASBA Bank A/c No./UPI ID	_____
Bank Name & Branch	_____		Stamp and Signature of SCSB Branch
Received from Mr./Ms./M/s.	_____		
Telephone / Mobile	_____	Email	_____

TEAR HERE

	PRAMODINI MEDICARE LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - NR			Stamp & Signature of Members of the Syndicate/ Sub - Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder _____ _____ _____
	No. of Equity Shares	Option 1	Option 2		
	Bid Price (₹)	Option 3			
	Additional Amount Blocked (₹ in figures)				
ASBA Bank A/c No. /UPI ID _____				Bid cum Application Form No.	
Bank Name & Branch _____					
Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.					